KELIX bio, a company wholly owned by Mubadala Investment Company, has acquired DiabTec LLC, a subsidiary of Julphar.
This acquisition enhances Mubadala’s biologicals portfolio and establishes its role in biomanufacturing across the MENA region. DiabTec’s facility includes 20,000-liter drug substance reactors and a separate cartridge fill-finish facility for drug products, built to EU/US FDA standards.
The acquisition follows KELIX bio’s recent purchase of four GlobalOne Healthcare Holding assets, marking its fifth strategic acquisition since being acquired by Mubadala in March 2024.
